UNSPSC 51293102: Iproclozide

This classification denotes a monoamine oxidase inhibitor and antidepressant agent with the molecular formula C11H15ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1II9D6CB3J, chemically known as acetic acid, (p-chlorophenoxy)-, 2-isopropylhydrazide but generally known as iproclozide, which bears US NIH Compound Identifier 19063. European Medicines Agency schedules Iproclozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08280MIG.

UNSPSC 51293102 Iproclozide, a Commodity code, nominally names a specific pharmaceutical compound but does not reflect the actual procurement activity appearing under this code in state and local solicitations. Recent opportunities tagged to this code involve acquisition of pharmaceutical products and drug-management systems — principally naloxone, safe drug deactivation systems, and multi-source generic pharmaceuticals with over-the-counter products — rather than iproclozide specifically. State and local issuers pursuing these procurements include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work involves sourcing finished pharmaceutical products for public health and safety initiatives, requiring vendors to meet manufacturing compliance standards (cGMP, DSCSA, FDA approval), maintain authorized distribution relationships, and deliver products to designated public facilities with quarterly or ongoing supply schedules.

The geographic spread of recent activity spans Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a regional vehicle serving multiple states including Oregon. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding; the Texas Health and Human Services Commission's Request for Information HHS0017013 (posted April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Department of Administration's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multistate contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards effective July 1, 2026. The MMCAP procurement emphasizes price competitiveness (weighted at 75 percent of evaluation), cGMP and DSCSA certification, and maintenance of chargeback relationships with authorized distributors.